Agios Pharmaceuticals (NASDAQ:AGIO) saw its stock jump 14.7% in pre-market trading on Wednesday following a landmark decision by the U.S. Food and Drug Administration. The regulatory body has granted approval for AQVESME, the company’s novel treatment for anemia in adult patients suffering from alpha- or beta-thalassemia. This approval positions the drug as the first and […]
